Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer
Practical Radiation Oncology · 2026
DOI: 10.1016/j.prro.2025.05.007 ↗Kurz gefasst
Fachartikel in der Zeitschrift Practical Radiation Oncology, 2026. Verfasst von Helena B Z Logar und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, HM Hospitales, Madrid, Spain; Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Sloveni…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiosurgery, Patient Reported Outcome Measures. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study evaluated the feasibility and tolerability of SABR in patients with high- and very-high-risk prostate cancer. METHODS AND MATERIALS: A prospective study included patients with high-risk and N1 prostate cancer. SABR was delivered as 40 Gy in 8 Gy fractions, with optional elective nodal irradiation (26 Gy in 5.2 Gy fractions) and a 40 Gy nodal boost for N1 disease. The treatment protocol involved 24 to 36 months of androgen deprivation therapy, premedication with alpha-1 receptor antagonists, and dexamethasone (4 mg on treatment days). Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events v5.0, while quality of life was assessed using the EORTC QLQ-C30 and QLQ-PR25 questionnaires at the final check-up. RESULTS: The study included 96 patients (median age 77.2 years) with a median follow-up of 29.8 months. Elective nodal radiation therapy was delivered to 66.7% of patients, and 16.8% received a nodal boost. Acute grade 2 (G2) genitourinary and gastrointestinal (GI) events occurred in 5.2% and 7.3% of patients, respectively, with no grade ≥3 acute events. Late grade ≥2 genitourinary and GI events were observed in 7.8% and 15.7% of patients, respectively, including 1 grade 4 GI event. Common late symptoms included nocturia and rectal bleeding. Most patients (86.5%) reported no or minor difficulties posttreatment, though challenges with sexual activity, nocturia, and incontinence were noted. Physicians underestimated urgency and nocturia and overestimated rectal bleeding. CONCLUSIONS: SABR delivering 40 Gy in 5 fractions is feasible and well-tolerated for high-risk prostate cancer, with minimal additional toxicity from elective nodal irradiation and a boost to N1 disease. These findings support SABR as an effective treatment, warranting further long-term studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, HM Hospitales, Madrid, Spain; Department of Radiation Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubliana, Ljubliana, Slovenia.
- Department of Radiation Oncology, HM Hospitales, Madrid, Spain; Faculty of Health, Universidad Camilo Jose Cela, Madrid, Spain. Electronic address: angel.monteroluis@gmail.com.
- Department of Radiation Oncology, HM Hospitales, Madrid, Spain.
- Department of Medical Physics, HM Hospitales, Madrid, Spain.
- Department of Radiation Oncology, HM Hospitales, Madrid, Spain; Faculty of Health, Universidad Camilo Jose Cela, Madrid, Spain.
Zitieren
APA
Logar, H. B. Z., Montero, A., Hernando, O., Lopez, M., Valero, J., Ciervide, R., Alvarez, B., Chen-Zhao, X., Sanchez, E., Garcia-Aranda, M., Saiz, C., Zucca, D., Alonso, L., Sanchez, M., Alonso, R., Fernandez-Leton, P., & Rubio, C. (2026). Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2025.05.007
Vancouver
Logar HBZ, Montero A, Hernando O, Lopez M, Valero J, Ciervide R, et al. Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer. Practical Radiation Oncology. 2026. doi:10.1016/j.prro.2025.05.007
BibTeX
@article{Logar2026,
author = {Logar, Helena B Z and Montero, Angel and Hernando, Ovidio and Lopez, Mercedes and Valero, Jeannette and Ciervide, Raquel and Alvarez, Beatriz and Chen-Zhao, Xin and Sanchez, Emilio and Garcia-Aranda, Mariola and Saiz, Carmen and Zucca, Daniel and Alonso, Leyre and Sanchez, Miguel and Alonso, Rosa and Fernandez-Leton, Pedro and Rubio, Carmen},
title = {Clinician- and Patient-Reported Outcomes of Stereotactic Ablative Radiation Therapy for High-Risk Prostate Cancer},
journal = {Practical Radiation Oncology},
year = {2026},
doi = {10.1016/j.prro.2025.05.007}
}
EUVIMED